JP2015516429A - アルファ７ニコチン性アセチルコリン受容体アロステリック調節因子、それらの誘導体およびその使用 - Google Patents
アルファ７ニコチン性アセチルコリン受容体アロステリック調節因子、それらの誘導体およびその使用 Download PDFInfo
- Publication number
- JP2015516429A JP2015516429A JP2015511659A JP2015511659A JP2015516429A JP 2015516429 A JP2015516429 A JP 2015516429A JP 2015511659 A JP2015511659 A JP 2015511659A JP 2015511659 A JP2015511659 A JP 2015511659A JP 2015516429 A JP2015516429 A JP 2015516429A
- Authority
- JP
- Japan
- Prior art keywords
- amino
- heterocycloalkyl
- cycloalkyl
- heterocycloalkenyl
- cycloalkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(C(N(*)*)=O)=C(*)CCCC* Chemical compound CCC(C(N(*)*)=O)=C(*)CCCC* 0.000 description 9
- LPMMTQCMSRCXIU-UHFFFAOYSA-N O=C(c1c(NCc(cc2)cc(F)c2F)nccc1)N(CC1)c(cc2)c1cc2Cl Chemical compound O=C(c1c(NCc(cc2)cc(F)c2F)nccc1)N(CC1)c(cc2)c1cc2Cl LPMMTQCMSRCXIU-UHFFFAOYSA-N 0.000 description 1
- MVPWHOSZMADCDQ-UHFFFAOYSA-N O=C(c1cccnc1NCc1ccccc1)Nc1ccc(C(F)(F)F)cc1 Chemical compound O=C(c1cccnc1NCc1ccccc1)Nc1ccc(C(F)(F)F)cc1 MVPWHOSZMADCDQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644318P | 2012-05-08 | 2012-05-08 | |
| US201261644411P | 2012-05-08 | 2012-05-08 | |
| US61/644,318 | 2012-05-08 | ||
| US61/644,411 | 2012-05-08 | ||
| US201261645935P | 2012-05-11 | 2012-05-11 | |
| US61/645,935 | 2012-05-11 | ||
| US201361801544P | 2013-03-15 | 2013-03-15 | |
| US61/801,544 | 2013-03-15 | ||
| PCT/US2013/040117 WO2013169889A1 (en) | 2012-05-08 | 2013-05-08 | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015516429A true JP2015516429A (ja) | 2015-06-11 |
| JP2015516429A5 JP2015516429A5 (enExample) | 2016-06-23 |
Family
ID=48430966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511659A Pending JP2015516429A (ja) | 2012-05-08 | 2013-05-08 | アルファ７ニコチン性アセチルコリン受容体アロステリック調節因子、それらの誘導体およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150099758A1 (enExample) |
| EP (1) | EP2846803B1 (enExample) |
| JP (1) | JP2015516429A (enExample) |
| KR (1) | KR20150008891A (enExample) |
| CN (1) | CN104334175A (enExample) |
| AU (1) | AU2013259565A1 (enExample) |
| BR (1) | BR112014027561A2 (enExample) |
| CA (1) | CA2871651A1 (enExample) |
| EA (1) | EA201491857A1 (enExample) |
| HK (1) | HK1208154A1 (enExample) |
| IN (1) | IN2014MN02121A (enExample) |
| MX (1) | MX2014013499A (enExample) |
| SG (1) | SG11201406914XA (enExample) |
| WO (1) | WO2013169889A1 (enExample) |
| ZA (1) | ZA201408847B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2977375A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| CN106715423A (zh) * | 2014-07-25 | 2017-05-24 | 拜耳制药股份公司 | 氨基取代的异噁唑 |
| EP2977377A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP2977376A1 (en) * | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| CN107398300B (zh) * | 2017-07-24 | 2020-08-21 | 中国科学院化学研究所 | 芳香族酰胺芳环c-h键直接氨基化反应的方法 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| PH12022550361A1 (en) | 2019-08-14 | 2023-02-27 | Incyte Corp | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
| WO2022096990A1 (en) * | 2020-11-05 | 2022-05-12 | Cadila Healthcare Limited | Novel hetrocyclic compounds |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001083460A1 (en) * | 2000-04-28 | 2001-11-08 | Tanabe Seiyaku Co., Ltd. | Cyclic compounds |
| JP2003520853A (ja) * | 2000-01-27 | 2003-07-08 | ノバルティス アクチエンゲゼルシャフト | ２−アミノ−ニコチンアミド誘導体 |
| JP2004531473A (ja) * | 2001-01-12 | 2004-10-14 | アムジエン・インコーポレーテツド | Ｎ−ピリジルカルボキサミド誘導体及びそれらを含有する医薬組成物 |
| JP2008525524A (ja) * | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
| WO2011044157A1 (en) * | 2009-10-06 | 2011-04-14 | Biogen Idec Ma Inc. | Heterocyclic compounds useful as pdk1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| DE602006020979D1 (en) * | 2005-01-14 | 2011-05-12 | Chemocentryx Inc | Heteroarylsulfonamide und ccr2 |
| US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| AU2009237650B2 (en) * | 2008-04-17 | 2012-05-31 | Proximagen Limited | Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 |
| GB201106829D0 (en) * | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
-
2013
- 2013-05-08 KR KR20147033675A patent/KR20150008891A/ko not_active Withdrawn
- 2013-05-08 SG SG11201406914XA patent/SG11201406914XA/en unknown
- 2013-05-08 CN CN201380029104.9A patent/CN104334175A/zh active Pending
- 2013-05-08 BR BR112014027561A patent/BR112014027561A2/pt not_active IP Right Cessation
- 2013-05-08 MX MX2014013499A patent/MX2014013499A/es unknown
- 2013-05-08 CA CA2871651A patent/CA2871651A1/en not_active Abandoned
- 2013-05-08 US US14/398,968 patent/US20150099758A1/en not_active Abandoned
- 2013-05-08 IN IN2121MUN2014 patent/IN2014MN02121A/en unknown
- 2013-05-08 WO PCT/US2013/040117 patent/WO2013169889A1/en not_active Ceased
- 2013-05-08 AU AU2013259565A patent/AU2013259565A1/en not_active Abandoned
- 2013-05-08 EA EA201491857A patent/EA201491857A1/ru unknown
- 2013-05-08 HK HK15108755.1A patent/HK1208154A1/xx unknown
- 2013-05-08 EP EP13722661.9A patent/EP2846803B1/en not_active Not-in-force
- 2013-05-08 JP JP2015511659A patent/JP2015516429A/ja active Pending
-
2014
- 2014-12-03 ZA ZA2014/08847A patent/ZA201408847B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003520853A (ja) * | 2000-01-27 | 2003-07-08 | ノバルティス アクチエンゲゼルシャフト | ２−アミノ−ニコチンアミド誘導体 |
| WO2001083460A1 (en) * | 2000-04-28 | 2001-11-08 | Tanabe Seiyaku Co., Ltd. | Cyclic compounds |
| JP2004531473A (ja) * | 2001-01-12 | 2004-10-14 | アムジエン・インコーポレーテツド | Ｎ−ピリジルカルボキサミド誘導体及びそれらを含有する医薬組成物 |
| JP2008525524A (ja) * | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
| WO2011044157A1 (en) * | 2009-10-06 | 2011-04-14 | Biogen Idec Ma Inc. | Heterocyclic compounds useful as pdk1 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014013499A (es) | 2015-11-13 |
| EA201491857A1 (ru) | 2015-04-30 |
| BR112014027561A2 (pt) | 2017-06-27 |
| EP2846803A1 (en) | 2015-03-18 |
| WO2013169889A1 (en) | 2013-11-14 |
| KR20150008891A (ko) | 2015-01-23 |
| AU2013259565A1 (en) | 2014-11-13 |
| CN104334175A (zh) | 2015-02-04 |
| US20150099758A1 (en) | 2015-04-09 |
| ZA201408847B (en) | 2015-12-23 |
| SG11201406914XA (en) | 2014-11-27 |
| HK1208154A1 (en) | 2016-02-26 |
| CA2871651A1 (en) | 2013-11-14 |
| IN2014MN02121A (enExample) | 2015-09-04 |
| EP2846803B1 (en) | 2017-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516429A (ja) | アルファ７ニコチン性アセチルコリン受容体アロステリック調節因子、それらの誘導体およびその使用 | |
| US8975407B2 (en) | α7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | |
| CN102271682B (zh) | 用于治疗疼痛的p2x3受体拮抗剂 | |
| TWI839461B (zh) | Il-17a調節物及其用途 | |
| CN113453681B (zh) | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 | |
| US20250376473A1 (en) | Prmts inhibitor and use thereof | |
| JP6964576B2 (ja) | 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 | |
| AU2018217488A1 (en) | Aminotriazolopyridines as kinase inhibitors | |
| EA020138B1 (ru) | Арилпиридины в качестве ингибиторов альдостеронсинтазы | |
| CN102099339A (zh) | 苯并氮杂衍生物及其作为组胺h3拮抗剂的用途 | |
| TW201043603A (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
| JP7120549B2 (ja) | Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ | |
| JP2010523725A (ja) | 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン | |
| CN113301901B (zh) | 四唑啉酮取代的类固醇及其用途 | |
| CN103917534A (zh) | 作为h3受体抑制剂的包含哌啶和哌嗪环的氨基甲酸酯/脲衍生物 | |
| CN109983022A (zh) | 作为mGluR2负性别构调节剂的色满、异色满和二氢异苯并呋喃衍生物、组合物及其用途 | |
| IL322853A (en) | History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy | |
| CA3226724A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
| WO2017024996A1 (zh) | 羟基脒类衍生物、其制备方法及其在医药上的应用 | |
| JP7726591B2 (ja) | ボロン酸化合物 | |
| TW201625608A (zh) | 作為ｇｌｙｔ１抑制劑之經取代２，４，５，６－四氫吡咯并［３，４－ｃ］吡唑及４，５，６，７－四氫－２ｈ－吡唑并［４，３－ｃ］吡啶化合物 | |
| JP2015516431A (ja) | アルファ７ニコチン性アセチルコリンアロステリック調節因子、それらの誘導体およびその使用 | |
| WO2011038662A1 (zh) | 作为trpv1阻断剂的化合物、药物组合物及其医药用途 | |
| JP2024508924A (ja) | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅの治療において有用なジアゼピン誘導体 | |
| TWI906428B (zh) | 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160506 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160506 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170131 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170905 |